What are the clinically important encapsulated bacteria, associated risk factors, and recommended prevention and treatment strategies?

Encapsulated Bacteria: Clinical Overview

Major Pathogenic Species

The clinically important encapsulated bacteria are Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae, and Streptococcus agalactiae (Group B Streptococcus), which have historically caused the majority of severe invasive infections including bacteremia and meningitis in children and adults. 1

Additional encapsulated pathogens include:

• Salmonella typhi 2
• Klebsiella pneumoniae 3

Virulence Mechanisms

The polysaccharide capsule functions as the primary virulence factor through multiple mechanisms:

• Blocks phagocytosis by preventing host immune cell recognition and binding to bacterial surface proteins 3
• Impairs complement opsonization by inhibiting C3b/iC3b deposition on the bacterial surface through both alternative and classical pathways 4
• Masks subcapsular antigens from antibody recognition, reducing IgG and C-reactive protein binding 4
• Inhibits conversion of C3b to iC3b on the bacterial surface, further reducing opsonization 4
• Prevents phagocytosis mediated by Fcγ receptors, complement receptors, and non-opsonic receptors 4

High-Risk Populations

Immunocompromised States

Patients with asplenia (anatomic or functional) face substantially increased risk of fulminant sepsis from encapsulated bacteria, with mortality rates of 40-70% for meningococcal infections. 5

Specific high-risk groups include:

• Asplenic patients: Both surgical splenectomy and functional asplenia (sickle cell disease, hemoglobinopathies) 5
• Complement deficiency: Particularly increases meningococcal disease risk 6
• Chronic GVHD patients: Requiring ongoing immunosuppressive therapy 7
• HIV-infected individuals: At risk at all CD4 counts 6
• Patients on prolonged corticosteroids: Creates relative immunocompromise 8
• Hypogammaglobulinemia: IgG levels <400-500 mg/dL 7
• Malignancy, diabetes, alcohol dependency: Cause relative immunocompromise 6

Age-Related Risk

• Children under 4 years: High risk for rapid TB meningitis progression and invasive H. influenzae disease (prior to Hib vaccine) 8, 9
• Adults over 50 years: Increased pneumococcal disease incidence 6
• Adults over 60 years: Higher Listeria risk (though Listeria is not encapsulated) 6
• Young adults (late teens/early 20s): Second peak of meningococcal disease 6

Anatomic and Clinical Risk Factors

• Skull fracture or CSF leak: Predisposes to recurrent pneumococcal meningitis 6
• Upper respiratory tract infections (otitis media, sinusitis): Often precede pneumococcal meningitis 6

Prevention Strategies

Vaccination Protocols for Asplenic Patients

Asplenic patients must receive sequential pneumococcal vaccination with PCV13 first, followed by PPSV23 6-12 weeks later, with PPSV23 revaccination every 6 years. 5

Complete vaccination schedule for asplenia:

• Pneumococcal: PCV13 → PPSV23 (6-12 weeks later) → PPSV23 revaccination every 6 years 5
• H. influenzae type b: Conjugated Hib vaccine (if not previously immunized per childhood schedule) 5
• Meningococcal: Tetravalent conjugated MenACWY vaccine with appropriate revaccination 5

Vaccination timing is critical: perform 2 weeks before planned splenectomy, or if not possible, 14 days after surgery—no additional benefit from longer delays. 5

Post-HSCT Vaccination

For hematopoietic stem cell transplant recipients 7:

• Pneumococcal vaccine: Administer 23-valent polysaccharide vaccine at 12 and 24 months post-HSCT 7
• Timing consideration: Limited immunogenicity in this population, but potential benefit justifies administration 7

Antibiotic Prophylaxis

Allogeneic HSCT recipients with chronic GVHD require antibiotic prophylaxis against encapsulated organisms (S. pneumoniae, H. influenzae, N. meningitidis) for the entire duration of active GVHD treatment. 7

Key prophylaxis considerations:

• TMP-SMZ for PCP prophylaxis also provides pneumococcal protection, though resistance exists 7
• Antibiotic selection should be guided by local resistance patterns 7
• Not recommended: Routine monthly IVIG >90 days post-HSCT without severe hypogammaglobulinemia (IgG <400 mg/dL) 7

Special Considerations for Eculizumab Therapy

For patients receiving eculizumab (complement inhibitor therapy) 10:

• Meningococcal vaccines required immediately: Both quadrivalent A, C, W, Y conjugate vaccine AND meningococcal B vaccine 10
• Antimicrobial prophylaxis mandatory: Penicillin or macrolides throughout eculizumab treatment 10
• Monitor continuously for fever, headache, neck stiffness indicating meningococcal infection 10

Clinical Presentations

Typical Infection Patterns

Encapsulated bacteria characteristically cause invasive infections including bacteremia, meningitis, pneumonia, and septic arthritis, with S. pneumoniae accounting for 82-92% of occult bacteremia cases in febrile children. 11

Specific presentations by organism:

• S. pneumoniae: Sinopulmonary infections, bacteremia, meningitis; often associated with concurrent upper respiratory infection 7, 6
• N. meningitidis: Meningitis, meningococcemia with characteristic rash 6
• H. influenzae: Dramatically reduced invasive disease post-Hib vaccine; remaining disease primarily from non-typeable strains causing mucosal infections 9

Occult Bacteremia in Children

In children aged 3-36 months with fever without source 11:

• Incidence: 1.5-2% develop occult bacteremia 11
• Sequelae risk: 5-20% of bacteremic patients develop significant complications (pneumonia, cellulitis, septic arthritis, osteomyelitis, meningitis, sepsis) 11
• Overall serious sequelae: 0.3% of all febrile children; 0.03% develop sepsis or meningitis 11

Treatment Principles

Empiric Antibiotic Selection

Antibiotic selection must be guided by local resistance patterns, as TMP-SMZ and penicillin resistance exists in pneumococcal strains. 7

Infection Control

• Appropriate isolation precautions for hospitalized patients with S. pneumoniae infections to prevent HSCT recipient exposure 7

Immune Support

Maintain trough serum IgG concentrations >400-500 mg/dL in hypogammaglobulinemic HSCT recipients through individualized IVIG dosing, monitored approximately every 2 weeks. 7

Common Pitfalls

• Delaying vaccination in asplenic patients: Must vaccinate 2 weeks pre-splenectomy or exactly 14 days post-splenectomy—not earlier, not later 5
• Using polysaccharide vaccines in children <2 years: Ineffective in this age group; conjugate vaccines required 7
• Discontinuing prophylaxis prematurely: Continue antibiotics throughout entire duration of active chronic GVHD treatment 7
• Forgetting meningococcal prophylaxis with eculizumab: Both vaccination AND antibiotic prophylaxis are mandatory 10
• Assuming Hib vaccine eliminated all H. influenzae disease: Non-typeable strains still cause mucosal infections 9